Endo International plc - Ordinary Shares (ENDP) Company Bio
Endo International plc focuses on branded and generic pharmaceuticals and devices worldwide. It operates through four segments: U.S. Branded Pharmaceuticals, U.S. Generic Pharmaceuticals, Devices, and International Pharmaceuticals. The company was founded in 1920 and is based in Dublin, Ireland.
ENDP Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for Endo International plc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Endo International plc ranked in the 11th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 87.17%. As for the metrics that stood out in our discounted cash flow analysis of Endo International plc, consider:
8% of the company's capital comes from equity, which is greater than just 4.14% of stocks in our cash flow based forecasting set.
Endo International plc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at 0.24. This coverage rate is greater than that of just 19.48% of stocks we're observing for the purpose of forecasting via discounted cash flows.
The weighted average cost of capital for the company is 17. This value is greater than 98.58% stocks in the Healthcare sector that generate free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
CPIX, CPHI, CMD, OSMT, and CRY can be thought of as valuation peers to ENDP, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.